The detection of BKPyV genotypes II and IV after renal transplantation as a simple tool for risk assessment for PyVAN and transplant outcome already at early stages of BKPyV reactivation.

[1]  A. Kribben,et al.  Impact of immune suppressive agents on the BK‐Polyomavirus non coding control region , 2018, Antiviral research.

[2]  A. Kribben,et al.  Impact of low‐level BK polyomavirus viremia on intermediate‐term renal allograft function , 2018, Transplant infectious disease : an official journal of the Transplantation Society.

[3]  M. Zalis,et al.  BK polyomavirus genotypes Ia and Ib1 exhibit different biological properties in renal transplant recipients. , 2018, Virus research.

[4]  R. Porcher,et al.  Neutralizing Antibody-Mediated Response and Risk of BK Virus-Associated Nephropathy. , 2017, Journal of the American Society of Nephrology : JASN.

[5]  A. Kistler,et al.  Correlation of BK Virus Neutralizing Serostatus With the Incidence of BK Viremia in Kidney Transplant Recipients , 2017, Transplantation.

[6]  J. Gill,et al.  Strategies to prevent BK virus infection in kidney transplant recipients , 2016, Current opinion in infectious diseases.

[7]  J. Delisle,et al.  BK Polyomavirus and the Transplanted Kidney: Immunopathology and Therapeutic Approaches , 2016, Transplantation.

[8]  S. Linnenweber-Held,et al.  Viral Origin, Clinical Course, and Renal Outcomes in Patients With BK Virus Infection After Living-Donor Renal Transplantation , 2016, Transplantation.

[9]  C. Bressollette-Bodin,et al.  BK polyomavirus: virus-cell interactions, host immune response, and viral pathogenesis. , 2015, Virologie.

[10]  H. Hirsch,et al.  Brincidofovir (CMX001) Inhibits BK Polyomavirus Replication in Primary Human Urothelial Cells , 2015, Antimicrobial Agents and Chemotherapy.

[11]  R. Kaiser,et al.  Early identification of renal transplant recipients with high risk of polyomavirus-associated nephropathy , 2015, Medical Microbiology and Immunology.

[12]  C. Ponticelli.  The impact of cold ischemia time on renal transplant outcome. , 2015, Kidney international.

[13]  W. Schaffner,et al.  Sp1 Sites in the Noncoding Control Region of BK Polyomavirus Are Key Regulators of Bidirectional Viral Early and Late Gene Expression , 2015, Journal of Virology.

[14]  Y. Dong,et al.  Risk factors for BK virus infection and BK virus-associated nephropathy under the impact of intensive monitoring and pre-emptive immunosuppression reduction. , 2014, Transplantation proceedings.

[15]  J. Qiu,et al.  Recipient-Related Risk Factors for Graft Failure and Death in Elderly Kidney Transplant Recipients , 2014, PloS one.

[16]  N. Babel,et al.  European perspective on human polyomavirus infection, replication and disease in solid organ transplantation. , 2014, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[17]  C. Buck,et al.  BK Polyomavirus Genotypes Represent Distinct Serotypes with Distinct Entry Tropism , 2013, Journal of Virology.

[18]  A. Gaber,et al.  Screening for BK Viremia Reduces But Does Not Eliminate the Risk of BK Nephropathy: A Single-Center Retrospective Analysis , 2013, Transplantation.

[19]  P. Randhawa,et al.  BK Polyomavirus in Solid Organ Transplantation , 2013, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[20]  G. Russ,et al.  Polyomavirus BK Replication in De Novo Kidney Transplant Patients Receiving Tacrolimus or Cyclosporine: A Prospective, Randomized, Multicenter Study , 2012, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[21]  J. Sipley,et al.  Evaluation of a BK virus viral load assay using the QIAGEN Artus BK Virus RG PCR test. , 2012, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[22]  D. Kuypers.  Management of polyomavirus-associated nephropathy in renal transplant recipients , 2012, Nature Reviews Nephrology.

[23]  S. Sandrini,et al.  Quantitative viral load measurement for BKV infection in renal transplant recipients as a predictive tool for BKVAN. , 2011, The new microbiologica.

[24]  M. Imperiale,et al.  A system for the analysis of BKV non-coding control regions: application to clinical isolates from an HIV/AIDS patient. , 2010, Virology.

[25]  E. Woodle,et al.  Assessment of Efficacy and Safety of FK778 in Comparison With Standard Care in Renal Transplant Recipients With Untreated BK Nephropathy , 2010, Transplantation.

[26]  K. Khalili,et al.  Rare subtypes of BK virus are viable and frequently detected in renal transplant recipients with BK virus-associated nephropathy. , 2010, Virology.

[27]  P. Randhawa,et al.  Polyomavirus BK Neutralizing Activity in Human Immunoglobulin Preparations , 2010, Transplantation.

[28]  Ethan M Balk,et al.  KDIGO clinical practice guideline for the care of kidney transplant recipients: a summary. , 2010, Kidney international.

[29]  H. Hirsch,et al.  Leflunomide Inhibition of BK Virus Replication in Renal Tubular Epithelial Cells , 2009, Journal of Virology.

[30]  B. Ponte,et al.  Evolution of rejection rates and kidney graft survival: a historical analysis. , 2009, Transplantation proceedings.

[31]  Hans H Hirsch,et al.  The decade of polyomavirus BK-associated nephropathy: state of affairs. , 2009, Transplantation.

[32]  V. Sharma,et al.  Epidemiology of BK Virus in Renal Allograft Recipients: Independent Risk Factors for BK Virus Replication , 2008, Transplantation.

[33]  R. Munivenkatappa,et al.  Polyomavirus BK Versus JC Replication and Nephropathy in Renal Transplant Recipients: A Prospective Evaluation , 2007, Transplantation.

[34]  Qin Chen,et al.  An Asian Origin for Subtype IV BK Virus Based on Phylogenetic Analysis , 2007, Journal of Molecular Evolution.

[35]  Qin Chen,et al.  Relationships between BK virus lineages and human populations. , 2007, Microbes and infection.

[36]  L. Naesens,et al.  Adjuvant Low‐Dose Cidofovir Therapy for BK Polyomavirus Interstitial Nephritis in Renal Transplant Recipients , 2005, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[37]  M. Suthanthiran,et al.  Polyomavirus-Associated Nephropathy in Renal Transplantation: Interdisciplinary Analyses and Recommendations , 2005, Transplantation.

[38]  Qin Chen,et al.  Subtypes of BK virus prevalent in Japan and variation in their transcriptional control region. , 2004, The Journal of general virology.

[39]  N. Andrews,et al.  Population‐based study of antibody to the human polyomaviruses BKV and JCV and the simian polyomavirus SV40 , 2003, Journal of medical virology.

[40]  G. Deray,et al.  Tolérance rénale du cidofovir , 1999 .

[41]  J. Cherrington,et al.  Clinical uses of cidofovir , 1997, Reviews in medical virology.

[42]  L. Jin.  Rapid genomic typing of BK virus directly from clinical specimens. , 1993, Molecular and cellular probes.

[43]  W. Knowles,et al.  BK virus antigenic variants: Sequence analysis within the capsid VP1 epitope , 1993, Journal of medical virology.

[44]  C. Bagnis,et al.  [Renal tolerance of cidofovir]. , 1999, Therapie.